| Expression pattern: |
DN |
| Associated gene: |
March1 |
| Associated microRNA: |
miR-653 |
| Biological function: |
suppresses bladder cancer growth; inhibits proliferation |
| Molecular mechanism: |
acts as a competing endogenous RNA (miRNA sponge) to bind miR-653 and elevate March1 expression |
| Biological pathway or process: |
proliferation (inhibits); cell cycle (inhibits); ceRNA regulation (other) |
| Detected method: |
Q
S
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; RT-qPCR; Clinical Sample Validation; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Cell Cycle Assay; Annexin V/PI Flow Cytometry; In Vivo Animal Model; Western Blot; IHC (Immunohistochemistry); Survival Analysis; RNA-seq |
| Clinical significance: |
Higher levels of ciRs-6 consistently correlated with lower tumor grade and earlier T stage, and a higher level of ciRs-6 in bladder cancer positively correlated with better overall survival. |
| Description: |
ciRs-6 is down-regulated in bladder cancer and acts as a tumor suppressor by sponging miR-653 in the cytoplasm, thereby relieving repression of March1. Higher ciRs-6 expression is associated with better overall survival and less advanced clinicopathologic features. |
| Confidence score: |
0.8702 |